A phase 1b/2 dose escalation and expansion study of OP-1250 in combination with ribociclib or alpelisib in patients with advanced and/or metastatic estrogen receptor-positive (ER+)/HER2-negative (HER2-) breast cancer

被引：0
|
作者：
Borges, Virginia F.
Chan, Arlene
Lin, Nancy U.
Tonda, Margaret Eleanor
Shilkrut, Mark
Alemany, Carlos A.
机构：
[1] Univ Colorado, Canc Ctr, Aurora, CO USA
[2] Breast Canc Res Ctr WA, Nedlands, Australia
[3] Curtin Univ, Nedlands, Australia
[4] Dana Farber Canc Inst, Boston, MA USA
[5] Olema Oncol, San Francisco, CA USA
[6] AdventHlth Orlando, Orlando, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS1127
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Updated results from the phase I/II study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer
    Lin, N. U.
    Borges, V. F.
    Patel, M. R.
    Okera, M.
    Meisel, J.
    Wesolowski, R.
    Pluard, T.
    Miller, K. D.
    McCarthy, N. J.
    Conlin, A. K.
    Mahtani, R.
    Sabanathan, D.
    McCann, K. E.
    Roesch, E.
    Mathauda-Sahota, G.
    Schroeder, J.
    Hamilton, E. P.
    ANNALS OF ONCOLOGY, 2023, 34 : S338 - S338
  • [32] Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer
    Burstein, Harold J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (12): : 1176 - 1177
  • [33] Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer
    Burstein, Harold J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (26): : 2557 - 2570
  • [34] Clinical considerations for estrogen receptor-negative/ progesterone receptor-positive/HER2-negative (ER-PR+HER2-) breast cancer
    Rala de Paula, Bruno Henrique
    Crocamo, Susanne
    Bines, Jose
    TRANSLATIONAL BREAST CANCER RESEARCH, 2023, 4
  • [35] FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
    Shah, Anand
    Bloomquist, Erik
    Tang, Shenghui
    Fu, Wentao
    Bi, Youwei
    Liu, Qi
    Yu, Jingyu
    Zhao, Ping
    Palmby, Todd R.
    Goldberg, Kirsten B.
    Chang, C. J. George
    Patel, Paresma
    Alebachew, Elleni
    Tilley, Amy
    Pierce, William F.
    Ibrahim, Amna
    Blumenthal, Gideon M.
    Sridhara, Rajeshwari
    Beaver, Julia A.
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2018, 24 (13) : 2999 - 3004
  • [36] HS-10352 in hormone receptor-positive, HER2-negative advanced breast cancer: A phase 1 dose-escalation trial
    Ouyang, Quchang
    Wang, Ying
    Zhang, Jian
    Wu, Qiong
    Wei, Hongying
    Li, Chuan
    Qian, Xiaoling
    Hu, Xichun
    CANCER MEDICINE, 2023, 12 (24): : 21849 - 21860
  • [37] The somatic mutation profile of estrogen receptor-positive HER2-negative metastatic breast cancer in Brazilian patients
    Reinert, Tomas
    do Rego, Fernanda Orpinelli
    Silva, Matheus Costa e
    Rodrigues, Amanda Muniz
    Koyama, Fernanda Christtanini
    Goncalves, Aline Coelho
    Pauletto, Maiane Maria
    de Carvalho Oliveira, Leandro Jonata
    de Resende, Cristiano Augusto Andrade
    Landeiro, Luciana Castro Garcia
    Barrios, Carlos Henrique
    Mano, Max Senna
    Dienstmann, Rodrigo
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [38] A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancer
    Shatsky, Rebecca A.
    Batra-Sharma, Hemali
    Helsten, Teresa
    Schwab, Richard B.
    Pittman, Emily I.
    Pu, Minya
    Weihe, Elizabeth
    Ghia, Emanuela M.
    Rassenti, Laura Z.
    Molinolo, Alfredo
    Cabrera, Betty
    Breitmeyer, James B.
    Widhopf II, George F.
    Messer, Karen
    Jamieson, Catriona
    Kipps, Thomas J.
    Parker, Barbara A.
    BREAST CANCER RESEARCH, 2024, 26 (01)
  • [39] Ribociclib (RIB) plus endocrine therapy (ET) in Japanese women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC)
    Masuda, N.
    Noguchi, S.
    Ishikawa, T.
    Aruga, T.
    Kim, S. J.
    Toyama, T.
    Saeki, T.
    Saito, M.
    Yamanaka, T.
    Watanabe, J.
    Nakamura, S.
    Takahashi, M.
    Inoue, K.
    Gounaris, I.
    Han, Y.
    Samant, T. S.
    Gazdoiu, M.
    Ito, Y.
    ANNALS OF ONCOLOGY, 2018, 29
  • [40] First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC)
    Hortobagyi, G. N.
    Stemmer, S. M.
    Burris, H. A.
    Yap, Y. S.
    Sonke, G. S.
    Paluch-Shimon, S.
    Campone, M.
    Blackwell, K.
    Andre, F.
    Winer, E. P.
    Janni, W.
    Verma, S.
    Conte, P.
    Arteaga, C. L.
    Cameron, D.
    Xuan, F.
    Souami, F.
    Miller, M.
    Germa, C.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2016, 27
12345